Skip To Main Content
Alexzandra Morris on Muck Rack

Alexzandra Morris

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alexzandra

Contact Alexzandra, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

l -Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

|
By Jun Gong, Hayato Muranaka, So Yung Choi, Mourad Tighiouart, Shrikant S. Bhute, Ezinne Aja, Jonathan Jacobs, Aleksandr B. Stotland, Jennifer Van Eyk, Mouad Edderkaoui, Sunao Tanaka, Hideki Furuya, Arsen Osipov, Jeremy Lorber, Sandrine Billet, Johanna Ten Hoeve-Scott, Thomas G. Graeber, Stephen J Pandol, Andrew Hendifar, Neil A. Bhowmick, Omer H. M. Elmadbouh, Alexzandra Morris
| Nature Verified
Abstract Exogenous l-glutamine has preclinical antitumor activity although formal clinical translation has not been attempted. We conducted a single-arm phase 1 trial to assess the safety and preliminary efficacy of clinical-grade, US Food and Drug Administration-approved l-glutamine therapy with gemcitabine and nab-paclitaxel (GA) in participants with treatment-naive, advanced pancreatic cancer (n = 16).
Open in Who Shared Issue with article?
See all 1 articles